CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0782 (clinicaltrials.gov NCT No: NCT01236352)
Title:A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy,
Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects with
Myelofibrosis
Principal Investigator:Srdan Verstovsek
Treatment Agent:BMS-911543
Study Status:Closed
Study Description:The goal of Phase 1 of this clinical research study is to learn the highest
tolerable dose of BMS-911543 that can be given to patients with MF. The goal
of Phase 2 of this study is to learn if BMS-911543 can help to control MF. The
safety of BMS-911543 will also be studied. You are being asked to take part in
the Phase 1 portion of the study.

Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase I/Phase II
Treatment Agents:BMS-911543
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bristol-Myers Squibb Co.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults